(agsandrew via Shutterstock)

How psychedelic drugs could revolutionize American medicine

A DEA ban is dramatically hindering vital research into possible new treatments of mental disorders


--

Shares

Roni Jacobson
August 28, 2014 4:00PM (UTC)
This article was originally published by Scientific American.

Scientific AmericanAlmost immediately after Albert Hofmann discovered the hallucinogenic properties of LSD in the 1940s, research on psychedelic drugs took off. These consciousness-altering drugs showed promise for treating anxiety, depression, post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD) and addiction, but increasing government conservatism caused a research blackout that lasted decades. Lately, however, there has been a resurgence of interest in psychedelics as possible therapeutic agents. This past spring Swiss researchers published results from the first drug trial involving LSD in more than 40 years.

Advertisement:

Time for a Psychedelic Spring?
Although the freeze on psychedelic research is thawing, scientists say that restrictive drug policies are continuing to hinder their progress. In the U.S., LSD, psilocybin, MDMA, DMT, peyote, cannabis and ibogaine (a hallucinogen derived from an African shrub) are all classified as Schedule I illegal drugs, which the U.S. Drug Enforcement Administration defines as having a high potential for abuse and no currently accepted medical applications—despite extensive scientific evidence to the contrary. In a joint report released in June, the Drug Policy Alliance and the Multidisciplinary Association for Psychedelic Studies catalogue several ways in which they say that the DEA has unfairly obstructed research on psychedelics, including by overruling an internal recommendation in 1986 that MDMA be placed on a less restrictive schedule.

The DEA and the U.S. Food and Drug Administration maintain that there is insufficient research to justify recategorization. This stance creates a catch-22 by basing the decision on the need for more research while limiting the ability of scientists to conduct that research. The June report recommends transferring responsibility for drug scheduling from the DEA to another agency or nongovernmental organization without a history of antidrug bias, such as the U.S. National Academy of Sciences. No matter how it happens, until the drugs are reclassified, bringing psychedelics from research into clinical practice will be an uphill battle.

 

 


Roni Jacobson

MORE FROM Roni Jacobson

Related Topics ------------------------------------------

Dea Lsd Mental Health Psychedelic Drugs Scientific American War On Drugs

BROWSE SALON.COM
COMPLETELY AD FREE,
FOR THE NEXT HOUR

Read Now, Pay Later - no upfront
registration for 1-Hour Access

Click Here
7-Day Access and Monthly
Subscriptions also available
No tracking or personal data collection
beyond name and email address

•••


Fearless journalism
in your inbox every day

Sign up for our free newsletter

• • •